NCT03136055: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

NCT03136055
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older(Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients must have a NET to be eligible; Patient must have completed first line systemic chemotherapy
Exclusions: Patients with leptomeningeal disease; Patients with known, active, untreated central nervous system (CNS) metastases- see trial for details; Patients with prior immunotherapy of anti-PD-1 or anti-PD-L1/2
https://ClinicalTrials.gov/show/NCT03136055

Comments are closed.

Up ↑